Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 5
Submit an article Journal homepage
22
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Treatment of Refractory Acute Leukemia with Timed Sequential Chemotherapy Using Topotecan Followed by Etoposide+Mitoxantrone (T-EM) and Correlation with Topoisomerase II Levels

M.G. Mainwaring University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
L.M. Rimsza Department of Pathology, Division of Hematopathology, Gainesville, FL, USA
,
S.F. Chen Malcolm Randall (Gainesville), VA Medical Center Research Service, Gainesville, FL, USA
,
S.P. Gomez Malcolm Randall (Gainesville), VA Medical Center Research Service, Gainesville, FL, USA
,
F.W. Weeks Vero Beach Oncology, Vero Beach, FL 32964, USA
,
V. Reddy University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
J. Lynch University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
W.S. May University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
S. Kahn University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
J. Moreb University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
H. Leather University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
,
R. Braylan Department of Pathology, Division of Hematopathology, Gainesville, FL, USA
,
T.C. Rowe Department of Pharmacology, Gainesville, FL 32610, USA
,
K.J. Finiewicz University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
&
J.R. Wingard University of Florida College of Medicine, Division of Hematology/Oncology, Gainesville, FL, USA
 show all
Pages 989-999 | Published online: 01 Jul 2009

  • Lowenberg, B., Downing, J.R and Burnett. A. (1999) "Acute myeloid leukemia". N. Engl J. Med. 341(14), 1051-1062.
  • Estey, E.H. (2000) "Current therapy and outcome of patients with relapsed acute myeloid leukemia". Biol, Ther. Leuk. 1(2 3), 8.
  • Kaufmann, S.H., Karp. J.E., Jones, R.J., Miller. C.B., Schneider, E., Zwelling. L.A. Cowan. K., Wendel. K. and Burke. P.J. (1994) "Topoisomerase 11 levels and drug sensitivity in adult Acute Myelogenous Leukemia". Blood 83, 517-530.
  • Brown, O.A., McPherson, J.P. Gu, L., Hedley. D.W., Toso, R., Deuchars. K.L., Freedman. M.H. and Goldenherg, G.J (1995)"Relationship of DNA topoisomerase IIa and â expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukeinia cell lines". Cancer Res. 55, 78-83.
  • Beck, J., Niethammer. D. and Geckeler, V. (1996) "MDRl MRP. topoisomerase II alpha/beta, and cyclin A gene expression in acute and chronic leukemias". Leukemia 10, S39-S45
  • Gieseler, F., Glasmacher, A., Kample, D., Wandt. H., Nuessler, V., Valsamas. S., Kunze. J. and Wilms. K. (1996) "Tupoisomerase II activities in AML. blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines". Leukemia 10, 1177-1180.
  • Geller, R.B. Burke. P.J., Karp. J.F., Humphrey. R.I.,. Braine, H.G., Tucker, R.W., Fox, M.G., Zahurak, M., Morrell. L., Hall. K.L. and Piantadosi, S. (1989) "A two-step timed sequential treatment for acute myelocytic leukemia". Blood 74(5), 1499-1506.
  • Burke, P.J., Karp, J.f., Geller, R.B and Vaughan. W.P. (1989) "Cures of leukemia with aggressive postremission treatment: an update of limed sequential therapy (Ac-D Ac". Leukemin 3(10), 692 694.
  • Geller, R.B., Sural, R. Karp. J.E., Santos. G.W and Burke, P.J (1990) "Cure of acute mvelocytic leukemia in adults: n reality". Leukemia 4(5), 313-315
  • Burke, P.J., Vaughan. W.P. and Karp. I.E. (1980) "A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation". Blood 55(6), 960-968.
  • Vaughan, W.P. and Burke. P.J (1983) "Development of a cell kinetic approach tu curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model". Cancer Res. 43(5), 2005-2009.
  • Vaughan, W.P., Karp. J.E., and Burke. P.J. (1984) "Two-cycle timedsequential chemotherapy for adult acute nonlymphocytic leukemia". Blood 64(5), 975-980.
  • Karp, JE and Burke. P.J. (1986) "Growth response of residual leukemia after initial drug therapy". Cancer Res. 46(8), 4205-4207.
  • Woods, W.G., Kobrinsky. N., Buckley. J.D., Lee, J.W. Sanders. J., Neudorf, S., Gold. S. Barnard, D.R., DeSwarte, J. Dusenbery. K., Kalousek, D., Arthur. D.C and Lange. B.J (1986) "Timedsequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the children's cancer group", Blood 87, 4979-4989.
  • Castaigne, S., Archimbaud, F, Bordessoule, D., Fenaux, T.H., de Revel, T., Simon. M. Janvier. M., Renous. M., Grosbois, B., Dupriez, B., Zini. J.M., Tertian. G., Legros. M., Chastang, C.'. and Degos, L. (1996) "Sequential induction or double induction chemotherapy increases disease free survival compared to "1+7" chemotherapy in less than 50 years adults with acute myeloid leukemia (AML)". Blood 88, 291 a.
  • Amadori, S., Arcese. W., lsacchi, G., Melone, G. Petti. M.C., Monarca. B., Testi. A.M. and Mandelli. F. (1991) "Mitoxantrone, etoposide. and interunediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia".J Clin. Oncol. 9, 1210-1214.
  • Kantarjian, H.M., Beran. M., Ellis. A., Zwelling, L., O'Brien. S., Cazenave, L., Koller, C. Rios. M.B., Plunkett, W., Keating, M.J. and Estey, E.H. (1993) "Phase 1 study of topotecan, a new topisomerase inhibitor, in patients with refractory or relapsed acute leukemia". Blood 81, 1146-1151.
  • Rowinsky, E.K, Adjci. A., Donehower. R.C., Gore. S.D, Jones, R.J., Burke. P.J., Cheng, Y.C., Grochow. L.B. and Kaufmann. S.H. (1994) "Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia". J. Clin. Oncol. 12, 2193-2197.
  • Beran, M., Kantarjian, H., O'Brien, S., Koller, C., al-Bitar, M., Arbuck, S., Pierce. S., Moore, M., Abbruzzese, J.L. Andreerf. M., Keating, M. and Estey, E. (1996) "Topotecan. a topoisomerase inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia". Blood, 2473-2478.
  • Seiter, K., Feldman, E.J., Halicka, H.D, Traganos. I., Darzynkiewicz, Z. Lake, D. and Ahmed. T. (1997) "Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia". J. Clin. Oncol. 15(1), 44-51
  • Mainwaring, M.G., Weeks. K. Wingard, J.W., Lynch, J., Rimsza. L. and Braylan. R. (1998) "Topoisomerase 11 levels and DNA fragmentation of leukemia blasts from patients treated with timed sequential chemotherapy [abstract]". Blood 92, 234a.
  • Crump, M., Lipton. J., Medley, D., Sutton, D., Shepherd. F., Minden. M., Stewart K., Beare. S. and Eisenhauer, E. (1999) "Phase I trial of sequential lopotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study", leukemia 13(3), 343-347.
  • Vey, N., Kantarjian, H., Beran. M. O'Brien. S., Cortes. J., Koller. C. and Estey. E. (1999) "Combination of topotecan with cytarabine or etoposide in patients with refractor)' or relapsed acute myeloid leukemia: results of a randomized phase I/II study". Invest. NewDrugs 17(1), 89-95.
  • Whitaere, CM., Zborowska, E., Gordon. N.H., Mackay, W. and Berger. N.A. (1997) 'Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in scheduledependent process". Cancer Res. 57, 1425-1428.
  • Chen, S., Gomez., S., Mainwaring, M.G. (2001). Topotecan-induced topoisomerase IIa expression increases the sensitivity of the K562 cell line to subsequent etoposide plus mitoxantrone treatment. Paper Submitted to Cancer Chemotherapy Pharmacology. 6/4/01.
  • Kancherla, R.R., Nair, J.S., Ahmed. T., Durrani. H., Seiter, K., Mannancheril. A. and Tse-Dinh. Y.C. (2001) "Evaluation of topotecan and eloposide for non-Hodgkin lymphoma: correlation of topoisomeruse-DNA complex formation with clinical response", Cancer 91(3), 463-471.
  • Cheson, B.D., Cassileth, P.A., Head. D.R., Schiffer. C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever. M.R., Keating, M.J., Sawitsky. A., Stass, S., Weinstein. H. and Woods. W.G. (1990) "Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in Acute Myeloid leukemia", J CIin. Oncol. 8, 813-819.
  • van Warmerdam, L.J.C., Verweij, J., Rosing, I.I., Schellens. J.H.M., Maes, R.A.A. and Beijnen, J.H. (1994) "Limiting sampling models of topotecan pharmacokinetics". Ann. Oncol. 3, 259-264.
  • Rowinsky, E.K., Grochow, L.B., Hendricks, C.B., Ettinger, D.S., Forastiere, A.A., Hurowitz, L.A., McGuire, W.P., Sartorius. S.E.,Lubejko, B.C., Kaufmann, S.H. and Donnehower, R.C (1992) "Phase 1 pharmacologic study of topotecan: a novel topoisomerase inhibitor". J. Clin. Oncol. 10, 647-656.
  • Thomas, X. and Archinbaud, E. (1997) "Mitoxantrone in the treatment of acute myelogenous leukemia: a review". Hematol. Cell Ther. 39(4), 63-74.
  • Karanes, C., Kopecky, K.J., Head. D.R., Grever. M.R., Hynes. H.E., Kraut, E.H., Vial. R.H., Lichtin, A., Nand. S., Saintowski, W.E. and Appelbaum, F.R. (1999) "A phase III comparison of high dose ARA-C versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute leukemia. A Southwest Oncology Group Study". Leuk. Res. 23, 787-791.
  • Koller, C.A., Kantarjian, H.M., Thomas. D., O'Brien, S., Rios, M.B., Komblau, S., Murphy. S. and Keating, M. (1997) "The hyperCVAD regimen improves outcome in relapsed acute lymphoblastic leukemia", lsukemia 11, 2039-2043.
  • Kem, W., Schleyer. E., Unterhalt. M., Wormann, B., Buchoer, T. and Hiddemann. W. (1997) "High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refactory acute leukemia. Results of a clinical phase 11 study". Cancer 79, 59-65.
  • Ho, A.D., Lipp, T, Ehninger, G., llliger, H.J., Meyer. R. Freund, M. and Hunstein, W. (1988) "Combination of mitoxantrone and VP-16 in refractory AML- an active and well-tolerated regimen". J. Clin. Oncol. 6, 213-217.
  • Davis,S.M., Robson,C.N., Davies. S.L and Hieson, L.D. (1988) "Nuclear topoisomerase Il levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins". J. Biol Chem. 263, 17724-17729.
  • Goreyca, W., Bigman. K., Mittelman. A., Ahmed. T., Gong, J., Melamed. M.R. and Darzynkiewiez. Z. (1993) "Induction of DNA strand breaks associated with apoptosis during treatment of leukemias". Leukemia 7, 659-670.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.